IDEHU   05542
INSTITUTO DE ESTUDIOS DE LA INMUNIDAD HUMORAL PROF. RICARDO A. MARGNI
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Adenoviral vector encoding the catalytic domain of the cysteine protease cruzipain confers immunoprotection against infection by the parasite trypanosoma cruzi.
Autor/es:
ANDRES SANCHEZ ALVERTI; CARDOZO LANDABURU A; ANTONELLA BASTONE; NATACHA CERNY; EMILIO L MALCHIODI; BIVONA A; SILVIA I CAZORLA
Lugar:
Mar del Plata
Reunión:
Congreso; IXIV reunión anual internacional de la sociedad argentina de inmunología; 2016
Resumen:
Chagas Disease is caused by the protozoan Trypanosoma cruzi and it affects about 7 million people all over the world, particularly poor people in developing countries. Available drugs for treatment are only effective in the acute phase of the disease and have several adverse effects and high toxicity. The severity of the Chagas disease together with the lack of adequate chemotherapeutic treatment for the chronic infection justify the need to develop effective prophylactic and/or therapeutic vaccines. To this end, we evaluated in this work an immunization protocol using an adenoviral vector encoding the catalytic N-terminus domain of Cruzipain, T. cruzi?s main cysteine protease (AdNtCz), delivered by different administration routes. We also evaluated Salmonella enterica serovar Typhimurium aroA 7207 as another delivery system, encoding NtCz as well. Adenoviral vector encoding β-galactosidase from Escherichia coli (Adβgal) was employed as control group. After being challenged with the parasite, vaccinated mice showed reduced parasitemia (AUC control/AUC vaccinated = 3), increased survival rates and lower weight loss compared to control group. Most importantly, the Prime Boost protocol (1 dose AdNtCz + 1 dose of recombinant Cruzipain with CpG Oligodeoxynucleotide as adjuvant) showed 100% of survival against a lethal dose of parasites. These results suggest that AdNtCz conferred immunoprotection against infection.